...
首页> 外文期刊>Clinical Pharmacology and Therapeutics >Drug interactions as a cause of overanticoagulation on phenprocoumon or acenocoumarol predominantly concern antibacterial drugs.
【24h】

Drug interactions as a cause of overanticoagulation on phenprocoumon or acenocoumarol predominantly concern antibacterial drugs.

机译:药物相互作用是苯丙香酚或醋香豆酚过度抗凝的原因,主要涉及抗菌药物。

获取原文
获取原文并翻译 | 示例

摘要

BACKGROUND: The risk of hemorrhage when coumarin anticoagulants are used sharply increases when the international normalized ratio (INR) is > or = 6.0. Such overanticoagulation may be caused by drug interactions. We performed a case-control study among previously stable outpatients of an anticoagulation clinic using phenprocoumon or acenocoumarol to identify changes in the use of potentially interacting drugs related to overanticoagulation. METHODS: Three hundred case patients with INR values > or = 6.0 were compared with 302 randomly selected matched control subjects with INR values within the target zone. Information on changes in the use of 87 potentially interacting drugs in the 4 weeks before the index day was collected by interviewing patients and by reviewing the anticoagulant medical record. RESULTS: Forty-five potentially interacting drugs were not used in the 4-week study period, and only 15 drugs were used by at least 10 patients. For a number of drugs, too few patients had a relevant change in use to judge their association with overanticoagulation. A course of a combination product of sulfamethoxazole and trimethoprim strongly increased the risk of overanticoagulation (adjusted odds ratio, 24.2; 95% confidence interval [CI], 2.8 to 209.1; population attributable risk percentage [PAR%], 5.7%), especially in patients receiving acenocoumarol. Penicillins were associated with a risk of overanticoagulation of 2.4 (95% CI, 1.00 to 5.5); the corresponding PAR% was 3.4%. The effect was confined to amoxicillin (INN, amoxicilline) plus clavulanic acid. CONCLUSION: Drug interactions as a cause of overanticoagulation predominantly concerned antibacterial drugs. If possible, the use of sulfamethoxazole-trimethoprim and amoxicillin plus clavulanic acid should be avoided in patients receiving coumarins. If there is no therapeutic alternative available, increased monitoring of INR values is warranted to prevent overanticoagulation and potential bleeding complications.
机译:背景:当国际标准化比(INR)大于或等于6.0时,使用香豆素抗凝剂时发生出血的风险急剧增加。这种过度抗凝可能是由药物相互作用引起的。我们对以前稳定的抗凝门诊患者进行了病例对照研究,这些患者使用苯普鲁蒙或醋香豆酚来确定与过度抗凝有关的潜在相互作用药物的使用变化。方法:将INR值大于或等于6.0的300例患者与302例目标区域内具有INR值的随机选择的匹配对照受试者进行比较。通过访问患者并查阅抗凝药物记录,收集了在索引日前4周内使用87种可能相互作用的药物的使用变化信息。结果:在为期4周的研究期内未使用45种可能相互作用的药物,至少10位患者仅使用了15种药物。对于许多药物,很少有患者使用相关的改变来判断其与抗凝过度有关。一疗程磺胺甲恶唑和甲氧苄啶的组合产品会大大增加过度抗凝的风险(校正比值比为24.2; 95%置信区间[CI]为2.8至209.1;人群归因风险百分比[PAR%]为5.7%),尤其是在接受醋香豆酚的患者。青霉素与过度抗凝风险为2.4(95%CI,1.00至5.5)有关;相应的PAR%为3.4%。该作用仅限于阿莫西林(INN,阿莫西林)加克拉维酸。结论:药物相互作用是过度抗凝的原因,主要涉及抗菌药物。如果可能,在接受香豆素的患者中应避免使用磺胺甲恶唑-三甲氧苄啶和阿莫西林加克拉维酸。如果没有其他可用的治疗方法,则必须增加对INR值的监测,以防止过度抗凝和潜在的出血并发症。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号